________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.⁶ It is the first-in-class ARNI recommended for the treatment of chronic HFrEF and targets two essential pathways in a complementary manner.^{1, 6}

To learn more, review the Summary of Product Characteristics.⁵

For patients living with chronic heart failure, time is essential, so start with ENTRESTO (sacubitril/valsartan)^1-4

ARNI may be used as part of cornerstone HFrEF therapy with a BB, MRA and SGTL2i in the 2021 ESC guidelines for the treatment of chronic HFrEF patients¹

ENTRESTO is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

** Local reimbursement criteria apply

^†ESC: ARNI may be used first line as part of cornerstone HFrEF therapy with a BB, MRA and SGLT2i for the treatment of chronic HFrEF patients.¹

^‡ACC: ARNIs, ACE-inhibitors or ARBs are recommended as first-line therapy in patients with HFrEF to reduce morbidity and mortality. If patients have chronic symptomatic HFrEF with NYHA class II or III symptoms and they tolerate an ACEi or ARB, they should be switched to an ARNi because of improvement in morbidity and mortality.²

^§DISCLAIMER: This is a US guideline and should not be used to guide treatment decisions in Ireland.

*CaReMe UK: sacubitril/valsartan is recommended as a first-line treatment option for chronic HFrEF where ejection fraction is <35%.

ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta-blocker; CaReMe UK, Cardio-Renal-Metabolic Partnership UK; ESC, European Society of Cardiology; HFrEF, heart failure with reduced ejection fraction; MoA, mode of action; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium-glucose co-transporter 2 inhibitor.

References:

1. European Heart Journal (2021) 42, 35993726 ESC GUIDELINES doi:10.1093/1. eurheartj/ehab368
2. Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
3. CaReMe UK HF algorithm. Available at: https://www.britishcardiovascularsociety.org
4. Ponikowski P, et al. ESC Heart Fail 2014;1(1):4–25.
5. Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
6. ENTRESTO Summary of Product Characteristics. www.medicines.ie
7. Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
8. Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
9. McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
10. Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
11. Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
12. Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
13. Desai AS, et al. JAMA 2019;322(11):1077–1084.
14. Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
15. Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.